Eaton Vance Management trimmed its holdings in West Pharmaceutical Services Inc. (NYSE:WST) by 2.2% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 265,858 shares of the medical instruments supplier’s stock after selling 6,067 shares during the period. Eaton Vance Management owned 0.36% of West Pharmaceutical Services worth $32,825,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of the business. Bank of Montreal Can acquired a new stake in shares of West Pharmaceutical Services in the 2nd quarter worth $584,000. Janney Montgomery Scott LLC boosted its position in shares of West Pharmaceutical Services by 14.1% in the 2nd quarter. Janney Montgomery Scott LLC now owns 4,926 shares of the medical instruments supplier’s stock worth $489,000 after purchasing an additional 609 shares in the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of West Pharmaceutical Services by 113.3% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 6,417 shares of the medical instruments supplier’s stock worth $637,000 after purchasing an additional 3,408 shares in the last quarter. Alps Advisors Inc. acquired a new stake in shares of West Pharmaceutical Services in the 2nd quarter worth $206,000. Finally, Eqis Capital Management Inc. acquired a new stake in shares of West Pharmaceutical Services in the 2nd quarter worth $446,000. 92.62% of the stock is owned by institutional investors.
West Pharmaceutical Services stock opened at $109.56 on Monday. The company has a quick ratio of 2.23, a current ratio of 2.94 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $8.12 billion, a PE ratio of 39.41, a price-to-earnings-growth ratio of 4.10 and a beta of 1.19. West Pharmaceutical Services Inc. has a 1-year low of $82.74 and a 1-year high of $125.09.
West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, October 25th. The medical instruments supplier reported $0.76 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.70 by $0.06. The firm had revenue of $431.70 million during the quarter, compared to analysts’ expectations of $427.55 million. West Pharmaceutical Services had a return on equity of 15.78% and a net margin of 9.06%. As a group, equities research analysts expect that West Pharmaceutical Services Inc. will post 2.83 EPS for the current fiscal year.
A number of research firms have recently weighed in on WST. Zacks Investment Research raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $129.00 price objective for the company in a research report on Wednesday, August 8th. ValuEngine raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Wednesday, October 17th.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Featured Story: S&P 500 Index
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.